TY - JOUR
T1 - Prospective observational study of FKRP-related limb-girdle muscular dystrophy R9
T2 - A GRASP consortium study
AU - the GRASP-LGMD Consortium
AU - Alfano, Lindsay N.
AU - James, Meredith K.
AU - Grosfjeld Petersen, Kristine
AU - Rudolf, Karen
AU - Vissing, John
AU - Augsburger, Renee
AU - Mozaffar, Tahseen
AU - Jones, Aileen
AU - Butler, Amanda
AU - Laubscher, Katie M.
AU - Mockler, Shelley R.H.
AU - Mathews, Katherine D.
AU - Iammarino, Megan A.
AU - Reash, Natalie F.
AU - Pietruszewski, Lindsay
AU - Lowes, Linda P.
AU - Strahler, Talia
AU - Wicklund, Matthew
AU - Hunn, Stephanie
AU - Weihl, Conrad C.
AU - Sasidharan, Sandhya
AU - Currence, Melissa
AU - Statland, Jeffrey M.
AU - Stinson, Nikia
AU - Holzer, Megan
AU - Leung, Doris G.
AU - Lott, Donovan J.
AU - Kang, Peter B.
AU - Holsten, Scott
AU - Desai, Urvi
AU - Johnson, Nicholas E.
N1 - Publisher Copyright:
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2025/2
Y1 - 2025/2
N2 - Objective: Limb-girdle muscular dystrophy R9 (LGMDR9, formerly known as LGMD2I), caused by variants in the fukutin-related protein (FKRP) gene leads to progressive muscle weakness of the shoulder and pelvic limb-girdles and loss of motor function over time. Clinical management and future trial design are improved by determining which standardized clinical outcome assessments (COA) of function are most appropriate to capture disease presentation and progression, informing endpoint selection and enrollment criteria. The purpose of our study was to evaluate the cross-sectional validity and reliability of clinical outcome assessments in patients with FKRP-related LGMDR9 participating in the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP) natural history study. Methods: Enrolled patients completed a battery of COA on two consecutive days, including the North Star Assessment for limb girdle-type dystrophies (NSAD), the 100-m timed test (100 m), and the Performance of Upper Limb 2.0 (PUL). Results: A total of 101 patients with FKRP-related LGMDR9 completed COA evaluations. All functional COA were highly and significantly correlated even across constructs, except for the 9-hole peg test. Similarly, all tests demonstrated excellent test–retest reliability across 2-day visits. The NSAD and PUL demonstrate robust psychometrics with good targeting, ordered response thresholds, fit and stability, and limited dependency of items across the scales. Conclusions: This study has determined the suitability of several functional COA, cross-sectionally, in LGMDR9 to inform future trial design and clinical care.
AB - Objective: Limb-girdle muscular dystrophy R9 (LGMDR9, formerly known as LGMD2I), caused by variants in the fukutin-related protein (FKRP) gene leads to progressive muscle weakness of the shoulder and pelvic limb-girdles and loss of motor function over time. Clinical management and future trial design are improved by determining which standardized clinical outcome assessments (COA) of function are most appropriate to capture disease presentation and progression, informing endpoint selection and enrollment criteria. The purpose of our study was to evaluate the cross-sectional validity and reliability of clinical outcome assessments in patients with FKRP-related LGMDR9 participating in the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP) natural history study. Methods: Enrolled patients completed a battery of COA on two consecutive days, including the North Star Assessment for limb girdle-type dystrophies (NSAD), the 100-m timed test (100 m), and the Performance of Upper Limb 2.0 (PUL). Results: A total of 101 patients with FKRP-related LGMDR9 completed COA evaluations. All functional COA were highly and significantly correlated even across constructs, except for the 9-hole peg test. Similarly, all tests demonstrated excellent test–retest reliability across 2-day visits. The NSAD and PUL demonstrate robust psychometrics with good targeting, ordered response thresholds, fit and stability, and limited dependency of items across the scales. Conclusions: This study has determined the suitability of several functional COA, cross-sectionally, in LGMDR9 to inform future trial design and clinical care.
UR - http://www.scopus.com/inward/record.url?scp=85212230532&partnerID=8YFLogxK
U2 - 10.1002/acn3.52276
DO - 10.1002/acn3.52276
M3 - Article
C2 - 39675022
AN - SCOPUS:85212230532
SN - 2328-9503
VL - 12
SP - 332
EP - 344
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 2
ER -